Introduction
Ciprofloxacin has been demonstrated to have broad antimicrobial activity, excellent tissue penetration, long duration of action and good bioavailability (Bergan, 1988) . These factors increase the likelihood of therapeutic efficacy and make oral ciprofloxacin a potential alternative to parenteral antibiotics in patients with functioning gastrointestinal tracts. Ciprofloxacin may be particularly useful in treatment of nosocomial respiratory tract infections because most respiratory tract pathogens are susceptible. A large multicentre trial showed parenteral ciprofloxacin to be as efficacious (69% clinical response rate) as imipenem-cilastatin (59%) in the treatment of severe nosocomial pneumonia (Fink et al., 1994) . Studies have also shown the oral form of ciprofloxacin to have comparable cure rates to parenteral antibiotics in the sequential treatment (parenteral followed by oral form) of serious bacterial respiratory tract infections, limiting the need for parenteral antibiotics and leading to substantial cost savings (Khan & Basir, 1989; Paladino et al., 1991) .
Previously, we demonstrated that gastrointestinal absorption of ciprofloxacin is unpredictable in critically ill patients immediately after major abdominal procedures, when gut function is diminished (Cohn et al., 1995) . We felt that critically ill patients 872 S. M. Cohn et at. with functioning gastrointestinal tracts, as demonstrated by tolerance of tube feedings, would be likely to absorb oral drugs. Therefore, we hypothesized that ciprofloxacin administered via nasogastric tube would be sufficiently absorbed to achieve therapeutic serum concentrations in this intensive care unit population.
Materials and methods

Antibacterial agent
Ciprofloxacin (Bayer Corp., Pharmaceutical Division, West Haven, CT, USA) was administered in 750 mg doses via nasogastric tube every 12 h for 48 h (total of four doses). The tablets were pulverized and added to 50 mL of sterile water before administration. The nasogastric tube was flushed with 30 mL of sterile water to ensure that the entire dose was delivered into the stomach. After introduction of the drug into the stomach, the nasogastric tube was reattached to the feeding pump and Pulmocare enteral feedings were resumed. No other oral medications (e.g., carafate or antacids) were given during this study. The patients received stress ulcer prophylaxis in the form of H 2 receptor antagonists, intravenously.
Subjects
Seven subjects (two female, five male) with a mean age of 52 years (range 34-71) consented to participate in this investigation. Subjects were included in the study if they were at least eighteen years of age, required mechanical ventilation, were receiving parenteral antibiotics for treatment of a documented pneumonia (fever, leukocytosis, positive sputum, and new infiltrate on chest x-ray), and had tolerated tube feeding for at least forty-eight hours. Subjects received Pulmocare as their enteral feeding mixture (calcium = 1.04 mg/mL; magnesium = 0.62 mg/mL; iron = 0.02 mg/mL). Subjects were excluded from the study for any of the following reasons: (1) history of hypersensitivity to quinolones; (2) pregnant or lactating women; (3) receipt of ciprofloxacin within one week of this study; (4) receipt of another investigational drug within 4 weeks prior to drug administration; (5) renal impairment indicated by creatinine greater than 3.0 mg/dL or creatinine clearance less than 40 mL/min.; (6) significant liver dysfunction defined as total bilrubin greater than 3 mg%; (7) granulocytopenia with granulocytes less than 1 x 10 6 /L; (8) chronic inflammatory bowel disease; (9) history of pseudomembranous colitis; (10) concomitant administration of probenecid during the study. Prior approval for this protocol was obtained from the Human Investigation Committee, and written informed consent was obtained. Data regarding the subjects' age, weight, pre-existing medical conditions, and APACHE II score were tabulated (see Table I ).
Sampling
Blood samples were collected for drug assay from existing arterial or central venous catheters before administration of the drug and at 0.25, 0.5, 0.75, 1.0, 1.25, 2.0, 4.0, 12.0 h after doses one and four. Within 2h of phlebotomy, samples were centifuged (20 min at 3200 rpm at 4°C), and the supernatant stored in glass vials at -70°C. Samples were shipped on dry ice to Bayer Corporation for drug assay.
Assay
Ciprofloxacin assay was performed by Bayer Corporation, Pharmaceutical Division, Clinical Pharmacology Laboratory. Serum concentrations were determined by high-performance liquid chromatography (Krol, Noe, & Beermann, 1986) . The limit of sensitivity of this assay was 0.05 mg/L. The assay was linear over the range of 0.05-7.5 mg/L. The coefficient of variation associated with the intra-day precision and accuracy was less than 10% at all concentrations examined.
Statistical and pharmacokinetic analysis
Pharmacokinetic variables were determined using noncompartmental models. Maximum serum concentrations and time to maximum serum concentration were determined directly from the serum concentration time curve derived from the observed data following the first and last dose (steady state). The area under the curve values for each dose interval were determined by the log-linear trapezoidal method.
Results
The seven subjects had a mean APACHE II score of 9.3 (range 5-17) (see Table I ). The maximum serum concentration (CM,) , time to reach C™, (T^), and the area under the curve for serum concentration versus time from r=0-12h (AUCo-12) are listed in Table II for each subject. Values are means ± S.E.M.
When comparing mean data for all patients, pharmacokinetics for the first and fourth dose were similar (dose 1: C^ = 2.29 ± 0.24 mg/L, T^ = 1.0 ± 0.27 h, AUCo-12 = 9.90 ± 2.05 mg.h/L; dose 4: C^ = 2.23 ± 0.39 mg/L, T mtx =\.04± 0.22 h, AUCo-12 = 10.63 ± 2.11 mg.h/L). However, examination of the individual dose-response curves shows a moderate degree of variability.
Discussion
The principle finding of this study was that oral absorption of the 750 mg ciprofloxacin dose in critically ill patients was moderate, but variable. We chose to study enteric absorption of ciprofloxacin in mechanically ventilated patients with pneumonia because these individuals frequently have functioning gastrointestinal tracts and require antibiotic therapy. Pharmacokinetic analysis was performed on a heterogeneous group (in terms of patient age, type and severity of medical illnesses) which reflects the typical intensive care unit population.
Ciprofloxacin is well absorbed during enteral feeding in normal volunteers with a C^, of 2.92 ± 0.32 mg/L, and AUCV12 = 15.02 ± 1.55 mg.h/L which were similar to the findings noted in our critically ill population (Yuk et al., 1989) . Reduced gastrointestinal absorption of the drug with enteral feedings has been related to chelation by divalent cations (Mueller et al., 1994) . Ciprofloxacin absorption is diminished when patients are given Pulmocare when compared to Ensure or Osmolite, probably reflecting the fact that Pulmocare has twice the concentration of calcium and magnesium (Mueller et al., 1994) . In our study, serum ciprofloxacin concentrations after the initial study dose (C,™ = 2.29 ± 0.24 mg/L and AUC0-12 = 9.9 ± 2.05 mg.h/L) were similar to those seen in normal volunteers after receiving a 500 mg oral dose (C^, = 2.7 + 0.2 mg/L and AUC0-12 = 10.7 ± 0.8 mg.h/L) (Lettieri et al., 1992) . These serum levels were well above MICs for many important pathogenic bacteria. Chelation by divalent cations in the tube feeding solution probably contributed to the variability and reduction in drug absorption seen in our subjects. Use of alternative enteral feeding mixtures with lower concentrations of divalent cations or stopping tube feedings for a short period of time may result in improved drug absorption.
